# Evaluate the Efficacy and Safety of ABP-671 in Subjects With Chronic Kidney Disease and Hyperuricaemia

> **NCT07323095** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Atom Therapeutics Co., Ltd** · enrollment: 80 (estimated)

## Conditions studied

- Chronic Kidney Disease

## Interventions

- **DRUG:** ABP-671 plus febuxostat Group 1
- **DRUG:** ABP-671 plus febuxostat Group 2
- **DRUG:** ABP-671 Group
- **DRUG:** Placebo Group

## Key facts

- **NCT ID:** NCT07323095
- **Lead sponsor:** Atom Therapeutics Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-30
- **Primary completion:** 2027-10-31
- **Final completion:** 2028-01-31
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07323095

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07323095, "Evaluate the Efficacy and Safety of ABP-671 in Subjects With Chronic Kidney Disease and Hyperuricaemia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07323095. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*